Introduction
============

Colorectal cancer ranks as the third most common cancer worldwide, as approximately 1 million new cases are diagnosed annually.[@b1-dddt-9-4471] The median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) has been improved considerately in recent decades,[@b2-dddt-9-4471],[@b3-dddt-9-4471] mainly because of the introduction of new chemotherapeutic agents and targeted therapies.[@b4-dddt-9-4471],[@b5-dddt-9-4471]

Chemotherapeutic agents are widely used for patients with advanced disease to prolong survival, control symptoms, and improve the quality of life.[@b6-dddt-9-4471]--[@b9-dddt-9-4471] As the foundation of chemotherapy in advanced mCRC, oxaliplatin and irinotecan have exhibited clinical effects in the treatment of mCRC. Human epidermal growth factor receptor (EGFR) is a transmembrane cell surface glycoprotein[@b10-dddt-9-4471] that plays an important role in the proliferation and metastasis of colorectal cancer by activating various signaling pathways.[@b11-dddt-9-4471] Thus, EGFR has become the primary therapeutic target for this cancer. Panitumumab is a fully human monoclonal antibody directed against EGFR, and its activity in terms of a survival benefit has been proven.[@b12-dddt-9-4471] However, panitumumab appears to produce different clinical outcomes in the treatment of mCRC when combined with different chemotherapeutics. Beneficial effects were observed when panitumumab was combined with irinotecan-based chemotherapy, and negative effects were noted when the drug was combined with oxaliplatin-based chemotherapy. Moreover, the interaction between oxaliplatin and panitumumab remains unknown.

The *KRAS* gene status is considered a predictive marker of anti-EGFR monoclonal antibodies. Previous research illustrated that patients with mutant *KRA*S did not experience a clinical benefit of anti-EGFR therapy.[@b13-dddt-9-4471] The aim of this meta-analysis was to explore the efficacy and toxicities of adding panitumumab to chemotherapy in patients with mCRC according to *KRAS* status and assess the efficacy of panitumumab in combination with different chemotherapeutic partners.

Methods
=======

Literature search and inclusion criteria
----------------------------------------

The PubMed, Embase, and Web of Science databases were searched to identify studies (published before December 24, 2014) on the addition of panitumumab to chemotherapy in the treatment of mCRC. The following search terms were used: ("panitumumab" \[Supplementary Concept\] OR "panitumumab" \[All Fields\]) AND ("secondary" \[Subheading\] OR "secondary" \[All Fields\] OR "metastatic" \[All Fields\]) AND ("colorectal neoplasms" \[MeSH Terms\] OR ("colorectal" \[All Fields\] AND "neoplasms" \[All Fields\]) OR "colorectal neoplasms" \[All Fields\] OR ("colorectal" \[All Fields\] AND "cancer" \[All Fields\]) OR "colorectal cancer" \[All Fields\]). The search was limited to human studies and randomized controlled trials (RCTs). No language restriction was imposed. We also manually searched the reference lists of the included studies until no potentially eligible articles could be identified. Studies that met the following inclusion criteria were included: 1) study design, RCT; 2) study population, ≥18 years old with a diagnosis of adenocarcinoma of the colon or rectum; 3) intervention, chemotherapy with or without panitumumab; and 4) outcome measure, OS, progression-free survival (PFS), and overall response rate (ORR). If duplicate data were presented in several studies, only the most informative or complete articles were included.

Data extraction and outcome measures
------------------------------------

Two authors independently extracted the following data from each study: first author, treatment regimen, the number of patients (intervention/control), age range or mean age of the patients, type of blinding, type of controls, hazard ratios (HRs) with 95% confidence intervals (CIs) for OS, PFS, ORR, and the incidence of adverse events. A standardized Excel file was used for data extraction. Disagreements between the investigators were resolved by discussion and consensus. The primary outcome was PFS. Secondary outcomes included OS, ORR, and the incidence of adverse events.

Quality assessment
------------------

The methodological quality of the studies was independently scored by Ruo-feng Liang and Lei-lei Zheng using a validated Jadad five-point scale.[@b14-dddt-9-4471] The scale consists of three items describing randomization (0--2 points), masking (0--2 points), and dropouts and withdrawals (0--1 point) in the report of an RCT.[@b14-dddt-9-4471] A score of 1 point is given for each of the points described. An additional point is given when the method of randomization and/or blinding is given and appropriate, whereas a point is deducted when the method is inappropriate. The quality scale ranges from 0 to 5 points. A higher score indicates better quality. Articles with ≥3 points were considered to have high quality.[@b15-dddt-9-4471]

Statistical analyses
--------------------

We assessed the overall efficacy of adding panitumumab to chemotherapy in the treatment of patients with mCRC based on the data from the included studies. PFS and OS were treated as time-to-event variables, and thus were expressed as HRs with 95% CIs for each study. The ORR and incidence of adverse events were treated as dichotomous variables and were expressed as risk ratios (RRs) with 95% CIs for each study. Heterogeneity across the studies was tested using *I*^2^ statistics, which quantitatively measured the degree of inconsistency across studies. *I*^2^ values of \<25%, approximately 50%, approximately 75%, and approximately 100% indicated no, low, moderate, and high heterogeneity, respectively.[@b16-dddt-9-4471] A fixed-effects model (Mantel--Haenszel method)[@b17-dddt-9-4471] was used, whereas a random-effects model (DerSimonian--Laird method)[@b18-dddt-9-4471] was used when significant heterogeneity existed (*I*^2^\>50%). A subgroup analysis was conducted on the basis of *KRAS* status and chemotherapeutic partners. The presence of publication bias was assessed using the Begg's test.[@b19-dddt-9-4471] A *P*-value of less than 0.05 was considered statistically significant. All statistical analyses were conducted using STATA software version 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Identification of eligible studies
----------------------------------

The initial search of the PubMed, Embase, and Web of Science databases yielded 566 relevant publications. Of these, 39 were excluded for duplicate records, and 458 were excluded after reviewing the title or abstract, leaving 69 articles for full-text review. In the review, eleven articles were excluded for the following reasons: one study used panitumumab in both arms,[@b20-dddt-9-4471] one study used bevacizumab and panitumumab in the intervention arm,[@b21-dddt-9-4471] three studies presented preliminary outcomes,[@b12-dddt-9-4471],[@b13-dddt-9-4471],[@b22-dddt-9-4471] and six articles had single-arm study designs.[@b23-dddt-9-4471]--[@b28-dddt-9-4471] Finally, four studies[@b29-dddt-9-4471]--[@b32-dddt-9-4471] that met the inclusion criteria were included in this meta-analysis. The flowchart of the search strategy is shown in [Figure 1](#f1-dddt-9-4471){ref-type="fig"}.

Study characteristics and quality assessment
--------------------------------------------

The main characteristics of the four RCTs included in the meta-analysis are presented in [Table 1](#t1-dddt-9-4471){ref-type="table"}. These studies were published between 2008 and 2014. The sample sizes of the studies ranged from 427 to 1,096 patients (total, 3,066 patients). The clinical characteristics were generally balanced between the intervention and control arms of each study. The four studies tested the *KRAS* mutation status of the tumors using allele-specific polymerase chain reaction. Adverse events were graded using the common Terminology Criteria for Adverse Events (version 3.0) with modifications for specific skin- and nail-related toxicities.[@b33-dddt-9-4471] The median Jadad score of the included studies was 3 (range: 3--4).

Primary outcome: PFS
--------------------

All the four RCTs reported PFS in the study patients. The aggregated results of these studies suggested that the addition of panitumumab to chemotherapy significantly prolonged PFS in the treatment of patients with mCRC (HR =0.84, 95% CI =0.78--0.91, *P*=0.000) ([Figure 2](#f2-dddt-9-4471){ref-type="fig"}). Begg's test and the funnel plot revealed no evidence of obvious publication bias (*Z*=0.707, *P*=0.946). Meanwhile, significant heterogeneity was identified (*I*^2^=83.6%, *P*=0.00). Subsequently, we performed subgroup analyses to explore potential sources of heterogeneity.

Subgroup analyses were conducted on the basis of *KRAS* status (wild-type or mutant *KRAS*). The results demonstrated a 29% reduction in the risk of progression with the addition of panitumumab to chemotherapy (HR =0.71, 95% CI =0.57--0.88, *P*=0.002; heterogeneity test: *I*^2^=79.9%, *P*=0.002) in patients with wild-type *KRAS* tumors ([Figure 3](#f3-dddt-9-4471){ref-type="fig"}). However, no beneficial effect was found in patients with *KRAS*-mutant tumors (HR =1.06, 95% CI =0.87--1.31, *P*=0.420; heterogeneity test: *I*^2^=58.9%, *P*=0.088).

Subgroup analyses were performed on the basis of the use of oxaliplatin-based chemotherapy and irinotecan-based chemotherapy. Pooled results illustrated that irinotecan-based chemotherapy significantly improved PFS (HR =0.84, 95% CI =0.76--0.94, *P*=0.002), whereas oxaliplatin-based chemotherapy had no effect (HR =1.05, 95% CI =0.74--1.48, *P*=0.781).

Secondary outcomes: OS and ORR
------------------------------

### Overall survival

All the four RCTs reported OS data. Pooled results revealed that adding panitumumab to chemotherapy did not significantly improve OS (HR =0.97, 95% CI =0.89--1.05, *P*=0.402) ([Figure 4](#f4-dddt-9-4471){ref-type="fig"}). Begg's test and the funnel plot revealed no evidence of obvious publication bias (*Z*=0.06, *P*=0.07).

Moreover, subgroup analyses identified no statistically significant improvement in OS in the subgroup of patients with wild-type *KRAS* tumors (HR =0.94, 95% CI =0.85--1.04, *P*=0.216). Nonsignificant results were observed for both irinotecan-based chemotherapy (HR =0.95, 95% CI =0.85--1.06, *P*=0.340) and oxaliplatin-based chemotherapy (HR =1.01, 95% CI =0.76--1.34, *P*=0.944).

### Overall response rate

All the four RCTs reported ORR data. The pooled analysis using a random-effects model indicated that adding panitumumab to chemotherapy significantly increased ORR (RR =2.18, 95% CI =1.13--4.22, *P*=0.021) ([Figure 5](#f5-dddt-9-4471){ref-type="fig"}). In the subgroup analysis, a similar outcome was found in patients with wild-type *KRAS* tumors (RR =2.43, 95% CI =1.21--4.90, *P*=0.013), but not in patients with mutant *KRAS* tumors (RR =0.99, 95% CI =0.81--1.20, *P*=0.894). The assessment of publication bias revealed no potential publication bias among the included studies (*Z*=0.734, *P*=0.132).

Adverse events
--------------

All the four RCTs reported the occurrence of adverse events. The pooled estimate calculated using a random-effects model demonstrated that the combination of panitumumab and chemotherapy was associated with significantly increased incidence rates of grade 3/4 skin toxicity (RR =19.79, 95% CI =12.65--30.95, *P*=0.00), hypokalemia (RR =3.31, 95% CI =1.31--8.35, *P*=0.011), mucositis (RR =3.52, 95% CI =1.84--6.77, *P*=0.00), hypomagnesemia (RR =18.79, 95% CI =5.90--59.84, *P*=0.00), diarrhea (RR =1.71, 95% CI =1.19--2.47, *P*=0.004), and fatigue (RR =2.02, 95% CI =1.30--3.15, *P*=0.002).

Discussion
==========

The current meta-analysis suggested that, compared with chemotherapy alone, the combination of panitumumab and chemotherapy significantly improved PFS (HR =0.84, 95% CI =0.78--0.91, *P*=0.000) and ORR (RR =2.18, 95% CI =1.13--4.22, *P*=0.021), but it did not prolong OS (HR =0.97, 95% CI =0.89--1.05, *P*=0.402). Additionally, in the subgroup analysis, a PFS benefit was observed in the wild-type *KRAS* population (HR =0.71, 95% CI =0.57--0.88, *P*=0.002), but not in the mutant *KRAS* population (HR =1.06, 95% CI =0.87--1.31, *P*=0.420). Similarly, the addition of panitumumab to irinotecan-based chemotherapy significantly prolonged PFS compared to chemotherapy alone (HR =0.84, 95% CI =0.76--0.94, *P*=0.002). By contrast, the addition of panitumumab to oxaliplatin-based chemotherapy conferred no significant benefit concerning PFS (HR =1.05, 95% CI =0.74--1.48, *P*=0.781).

According to this meta-analysis, patients receiving the combination of panitumumab and chemotherapy experienced significantly prolonged PFS compared to patients treated with chemotherapy alone. However, this significant benefit was not achieved when panitumumab was added to bevacizumab-based chemotherapy. In the RCT conducted by Hecht et al[@b21-dddt-9-4471] patients were randomly assigned to receive bevacizumab-based chemotherapy with or without panitumumab, and panitumumab-treated patients displayed decreased PFS (HR =1.27, 95% CI =1.06--1.52). Although the exact explanation for this result is not clear, the authors postulated several plausible hypotheses: 1) the existence of pharmacokinetic interactions between antibodies or between antibodies and chemotherapy; 2) toxicity was exacerbated by dual-pathway inhibition in the combination arm; and 3) the toxicity induced by the anti-EGFR antibodies and chemotherapy resulted in dose delays and reductions and increased the risk of death in the panitumumab arm.[@b21-dddt-9-4471]

In this meta-analysis, we found that irinotecan-based regimens significantly prolonged PFS in the treatment of mCRC. However, this beneficial effect was not found for oxaliplatin-based regimens. The reason why panitumumab is better paired with irinotecan than with other drugs remains unknown. In a recently published meta-analysis conducted by Zhou et al,[@b34-dddt-9-4471] cetuximab and panitumumab were found to have different effects when combined with different fluoropyrimidine regimens. The authors hypothesized that the addition of cetuximab may have reduced the dose intensity and thus affected the efficacy of capecitabine-based therapy.

Skin toxicity is a class effect of anti-EGFR treatment for both monoclonal antibodies and tyrosine kinase inhibitors.[@b35-dddt-9-4471],[@b36-dddt-9-4471] The development of skin toxicity is considered a predictive factor of clinical efficacy. Among panitumumab-treated patients, prolonged PFS and OS and a higher ORR are usually observed in those who develop grade 2--4 skin toxicity compared with those without skin toxicity. However, although the appearance of skin toxicity indicated the on-target activity associated with clinical benefits, it was also found in patients who did not benefit from treatment.

Some potential limitations in this meta-analysis should be considered. First, the data we abstracted were obtained from publications rather than individual patient data, making them less powerful for confirming the findings.[@b37-dddt-9-4471] However, according to the results of a correlation analysis,[@b38-dddt-9-4471] meta-analyses based on abstract data are strongly correlated with those based on individual patient data, indicating that abstract data are acceptable and that they could be used in place of individual patient data. Second, there was considerable heterogeneity among the included studies. The characteristics of the targeted populations, study designs, treatment schedules, and follow-up intervals varied greatly. All of these factors may lead to heterogeneity and potentially affect our results. Third, although we included all large trials assessing the efficacy of panitumumab plus chemotherapy in the treatment of patients with mCRC, caution should be taken when interpreting the results, as the analysis was based on a limited number of RCTs.

In conclusion, this meta-analysis confirmed the effects, as well as the acceptable safety profile, of adding panitumumab to chemotherapy on PFS and ORR in the treatment of patients with wild-type *KRAS* mCRC. However, considering the limited number of RCTs and the heterogeneity among the included studies, larger, better-designed RCTs are needed to substantiate the findings and investigate the predictive role of *KRAS* concerning the combination of panitumumab and chemotherapy for patients with mCRC.
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###### 

Characteristics of the studies included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Treatment group            Number of patients                                          Median age\                                                 Male/female                                                                                    WHO performance status (0/1/2+)                                                                Median follow-up\   Line of treatment   Jadad score
                                                                                                                             (range)                                                                                                                                                                                                                                                   (months)                                
  ----------------------------------- -------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ------------------- ------------------- -------------
  Amado et al[@b29-dddt-9-4471]       Panitumumab + BSC          208                                                         62.5 (29--82)[\*](#tfn1-dddt-9-4471){ref-type="table-fn"}   130/78                                                                                         96/84/28                                                                                       Not reported        Not reported        3

  BSC                                 219                        63.0 (32--81)[\*](#tfn1-dddt-9-4471){ref-type="table-fn"}   140/79                                                      77/109/33                                                                                                                                                                                                                             

  Douillard et al[@b30-dddt-9-4471]   Panitumumab + FOLFOX4      546                                                         62 (27--85)[\*](#tfn1-dddt-9-4471){ref-type="table-fn"}     362/184                                                                                        518[a](#tfn2-dddt-9-4471){ref-type="table-fn"}/28[b](#tfn3-dddt-9-4471){ref-type="table-fn"}   20                  First line          4

  FOLFOX4                             550                        61 (33--83)[\*](#tfn1-dddt-9-4471){ref-type="table-fn"}     332/218                                                     521[a](#tfn2-dddt-9-4471){ref-type="table-fn"}/28[b](#tfn3-dddt-9-4471){ref-type="table-fn"}                                                                                                                                          

  Peeters et al[@b31-dddt-9-4471]     Panitumumab + FOLFIRI      541                                                         60 (28--84)[\*](#tfn1-dddt-9-4471){ref-type="table-fn"}     321/220                                                                                        512[a](#tfn2-dddt-9-4471){ref-type="table-fn"}/29[b](#tfn3-dddt-9-4471){ref-type="table-fn"}   30                  Second line         3

  FOLFIRI                             542                        61 (29--86)[\*](#tfn1-dddt-9-4471){ref-type="table-fn"}     339/203                                                     506[a](#tfn2-dddt-9-4471){ref-type="table-fn"}/36[b](#tfn3-dddt-9-4471){ref-type="table-fn"}                                                                                                                                          

  Seymour et al[@b32-dddt-9-4471]     Panitumumab + irinotecan   230                                                         64 (57--70)                                                 160/70                                                                                         217[a](#tfn2-dddt-9-4471){ref-type="table-fn"}/13[b](#tfn3-dddt-9-4471){ref-type="table-fn"}   25.4                Not reported        3

  Irinotecan                          230                        63 (56--69)                                                 158/72                                                      217[a](#tfn2-dddt-9-4471){ref-type="table-fn"}/13[b](#tfn3-dddt-9-4471){ref-type="table-fn"}                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Data from wild-type patients.

Data from patients with an ECOG performance status of 0--1.

Data from patients with an ECOG performance status of 2.

**Abbreviations:** BSC, best supportive care; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX4, infusional fluorouracil, leucovorin, and oxaliplatin; WHO, World Health Organization.
